KneeLife

Focused nerve-procedure comparison

Genicular RFA versus PNS versus cryoneurolysis

These treatments all interact with peripheral pain signaling, but they are not interchangeable. RFA uses heat-based radiofrequency energy, PNS uses electrical stimulation, and cryoneurolysis uses controlled cold.

Device and clinical context matter. PNS may mean a temporary percutaneous system or an implanted system; the lead, treatment duration, restrictions, and later hardware implications differ. Cryoneurolysis used for chronic knee symptoms is a different pathway from perioperative cryoneurolysis used around knee replacement.

For pain after replacement, none of these should bypass evaluation for infection, fracture, loosening, instability, stiffness, implant or bone problems, extensor-mechanism concerns, or another correctable cause.

Open these options in the interactive workspace

Compare the roles side by side

These are discussion fields, not a score, ranking, candidacy decision, or universal treatment ladder.

Purpose, context, and prerequisites

Genicular nerve radiofrequency ablation

Pain-focused procedureNerve-targeted procedure

What it is trying to change

RFA applies radiofrequency energy near selected genicular sensory nerves to reduce pain signaling from the knee.

It does not repair cartilage, change alignment, stabilize an implant, treat infection, or correct another mechanical cause.

Strongest practical reason to discuss it

It offers a targeted outpatient pain procedure with broader clinical availability and a longer track record than several newer interventions.

Common clinical context

  • Knee OA symptoms when reconstruction is not wanted or appropriate now
  • Persistent pain after knee replacement only after urgent, infectious, implant, bone, stability, stiffness, and other correctable concerns have been evaluated

What must be confirmed

  • The knee pain pattern and the role of the targeted nerves
  • Whether a diagnostic block is appropriate and how its result will be interpreted
  • For a replaced knee, that a cause-focused orthopedic evaluation is sufficiently complete

Generally a poor fit when

  • An uninvestigated painful knee replacement
  • Infection, fracture, implant failure, major instability, severe stiffness, extensor-mechanism problem, or another correctable cause needing problem-directed care

Peripheral nerve stimulation

Pain-focused procedureNeuromodulation

What it is trying to change

PNS delivers electrical stimulation near a peripheral nerve to alter pain signaling and support function without intentionally destroying the nerve.

It does not correct infection, implant loosening, fracture, instability, stiffness, alignment, or damaged joint surfaces.

Strongest practical reason to discuss it

It can test a nerve-modulation strategy without ablating the nerve; temporary and implanted systems offer meaningfully different burdens.

Common clinical context

  • Persistent focal or neuropathic knee-region pain after a diagnosis-focused evaluation
  • Persistent pain after knee replacement when no clear correctable surgical target has been found

What must be confirmed

  • The anatomic nerve target and pain pattern
  • Temporary percutaneous versus implanted system
  • For a replaced knee, completion of urgent, infection, implant, bone, stability, stiffness, and other cause-focused evaluation

Generally a poor fit when

  • A correctable infection, fracture, implant, stability, stiffness, or extensor-mechanism problem
  • A request for stimulation before the pain source and device burden have been explained

Cryoneurolysis

Pain-focused procedureTemporary nerve interruption

What it is trying to change

Cryoneurolysis uses controlled cold near a peripheral nerve to temporarily interrupt pain-signal conduction until the nerve recovers.

It does not repair cartilage, correct mechanics, or establish that the treated nerve is the only pain source.

Strongest practical reason to discuss it

It offers a nonimplant nerve-targeted option whose effect is intended to fade as the treated peripheral nerve recovers.

Common clinical context

  • Knee OA pain in a program using a supported nerve-targeting protocol
  • Perioperative pain planning in selected pathways, which is different from treating chronic pain after replacement

What must be confirmed

  • The proposed nerve target and whether use is chronic-OA or perioperative
  • Product-specific labeling and expected duration
  • Skin, cold-sensitivity, bleeding, neurologic, and prior-surgery considerations

Generally a poor fit when

  • Using perioperative evidence as proof for chronic unexplained post-TKA pain
  • A correctable structural, infectious, vascular, or neurologic problem requiring another evaluation

Treatment, recovery horizon, and future options

Genicular nerve radiofrequency ablation

What treatment involves

Needles are positioned near selected sensory nerve targets and radiofrequency energy is used to interrupt or alter pain signaling; a diagnostic block may precede it.

Procedure or treatment burden

Outpatient needle-based procedure, usually with local anesthetic and image guidance; sedation and block protocols vary.

Time until benefit

Some relief may appear within days, but the result is commonly judged over several weeks.

Durability and repeatability

Relief can be temporary, incomplete, or absent; duration varies and nerve signaling can return.

Repeat ablation may be discussed after a meaningful response wears off, but requires renewed clinical review.

Reversibility or implanted material

No permanent implant is left; the targeted nerve signaling may recover over time.

Effect on future options

RFA generally preserves later orthopedic and pain-treatment options and does not reconstruct the joint.

Peripheral nerve stimulation

What treatment involves

One or more leads are placed near a peripheral nerve and connected to an external temporary stimulator or, for selected systems, an implanted pulse generator.

Procedure or treatment burden

Temporary systems require lead placement, external-device care, dressing management, and later lead removal; implanted systems add a permanent device and implantation/revision considerations.

Time until benefit

Benefit may be explored during the treatment period; the meaningful assessment window depends on system type and protocol.

Durability and repeatability

Temporary PNS may have carryover after lead removal in some patients; implanted systems can provide ongoing therapy but require device management. Individual durability is uncertain.

A temporary course or implanted-system revision is not an automatic repeat; reassessment is required.

Reversibility or implanted material

Temporary fine-wire leads are removed; implanted systems leave hardware and may need later revision or removal.

Effect on future options

PNS often preserves orthopedic options, but implanted hardware, lead location, infection history, and imaging compatibility can matter later.

Cryoneurolysis

What treatment involves

A probe creates a controlled cold zone near a selected superficial peripheral nerve, temporarily interrupting signal conduction while preserving the nerve's connective structure.

Procedure or treatment burden

Office or outpatient needle/probe procedure with local anesthetic; target mapping, number of cycles, and perioperative timing vary.

Time until benefit

Potential relief can begin early, but the response and duration vary by target, protocol, and context.

Durability and repeatability

The effect is temporary as nerve function returns; product labeling and trial follow-up do not guarantee a specific duration.

Repeat treatment may be technically possible after reassessment, but repeated numbness or nonresponse should not trigger automatic retreatment.

Reversibility or implanted material

No implant remains; sensation and nerve signaling are expected to recover over time.

Effect on future options

Cryoneurolysis generally preserves later orthopedic and pain-treatment options.

Risks, access, and technique variables

Genicular nerve radiofrequency ablation

Important risks

  • Procedure-site pain or bruising
  • Temporary numbness, neuritis, or altered sensation
  • Bleeding, infection, skin burn, or injury to nearby structures
  • No benefit or short-lived benefit

Lived-experience concerns

  • The diagnostic block and authorization process
  • A temporary pain flare
  • Uncertainty about duration
  • Different target and lesion protocols among programs

Insurance and cash-pay context

Coverage is more common than for many emerging procedures but varies by plan, diagnostic-block policy, technique, and prior authorization.

Technique variables

  • Diagnostic-block protocol and interpretation
  • Nerve targets
  • Conventional, cooled, or other radiofrequency method
  • Image guidance, lesion size, and sedation

Peripheral nerve stimulation

Important risks

  • Lead-site infection, bleeding, skin irritation, or pain
  • Lead movement, fracture, or loss of stimulation
  • Uncomfortable stimulation or no benefit
  • Implanted-device revision, removal, battery, and imaging considerations

Lived-experience concerns

  • Managing an external device and dressings
  • Activity limits that protect a lead
  • Learning stimulation settings
  • Insurance authorization and device-specific costs

Insurance and cash-pay context

Coverage and authorization vary sharply by diagnosis, temporary versus implanted system, device, and payer. Confirm the complete episode and follow-up costs.

Technique variables

  • Temporary versus implanted system
  • Nerve target and lead position
  • Ultrasound or fluoroscopic guidance
  • Programming and follow-up protocol

Cryoneurolysis

Important risks

  • Bruising, swelling, localized pain, numbness, or altered sensation
  • Skin injury, pigment change, or cold-related tissue injury
  • Dysesthesia, neuritis, weakness from unintended motor-nerve effect
  • No benefit or benefit shorter than hoped

Lived-experience concerns

  • A temporary numb patch
  • Uncertainty about target and duration
  • Difference between perioperative and chronic-pain use
  • Cash-pay variation

Insurance and cash-pay context

Coverage varies by payer, diagnosis, product, and treatment context; some programs use cash-pay pathways.

Technique variables

  • Target nerve
  • Probe/device
  • Freeze cycle and treatment zone
  • Chronic OA versus perioperative timing

Four separate maturity dimensions

Evidence, regulatory status, adoption, and access answer different questions. KneeLife does not combine them into a grade.

Genicular nerve radiofrequency ablation

Evidence maturitydeveloping

Trials report pain improvement, but a recent randomized-evidence review judged certainty low and average benefit modest, with uncertain durability and inconsistent functional change.

Regulatory or labeling maturitydeveloping

Radiofrequency systems and probes vary; confirm the device, technique, and whether the proposed use matches product labeling and local practice.

Clinical adoption maturityestablished

Genicular RFA is a familiar pain-medicine and PM&R pathway, although protocols vary.

Provider-access maturityestablished

KneeLife retains 30 source-backed RFA program records with native and postsurgical distinctions where documented.

Peripheral nerve stimulation

Evidence maturitydeveloping

Randomized evidence supports 60-day PNS for persistent pain after TKA in a small trial; evidence varies by pain condition, nerve target, and device type.

Regulatory or labeling maturitydeveloping

Temporary and implanted systems have device-specific indications, clearances, and instructions; do not treat PNS as one interchangeable product.

Clinical adoption maturitydeveloping

Use is growing in pain medicine and PM&R, but knee-specific pathways and target selection vary.

Provider-access maturitydeveloping

KneeLife retains 23 source-backed PNS records with device and postsurgical distinctions where documented.

Cryoneurolysis

Evidence maturityemerging

A 2017 sham-controlled OA trial was positive, while a 2025 double-blind trial did not show a clinically meaningful primary-endpoint advantage; technique and targets differed.

Regulatory or labeling maturityestablished

The current iovera labeling includes knee-OA pain relief for up to 90 days; this is a labeled upper limit, not a promised response.

Clinical adoption maturitydeveloping

Use remains technique- and context-specific, including chronic OA and perioperative pathways.

Provider-access maturitydeveloping

KneeLife retains nine source-backed cryoneurolysis program records; availability and exact technique still require confirmation.

What recovery may look like

Genicular nerve radiofrequency ablation

Before treatment

Review the diagnosis and prior workup, decide whether a diagnostic block is useful, and complete any authorization requirements.

Treatment or procedure day

Needles are placed with imaging near selected nerve targets; local anesthetic, stimulation testing, lesion method, and sedation vary.

First 72 hours

Local soreness, bruising, numbness, or a temporary pain flare can occur. Use the program's wound and activity instructions.

First two weeks

Procedure soreness usually settles while the treatment effect begins to declare itself; maintain the agreed rehabilitation plan.

Weeks two through six

Judge change in walking, sleep, work, and other goals rather than pain alone.

Later recovery

If benefit occurs, track its duration and what function it enables. If it wears off, reassess before repeating.

Expected time to benefit

Days to several weeks; lack of immediate relief does not by itself establish failure.

Return to work and activity

  • Many people resume light routine activity quickly, but heavy work and exercise follow the treating team's instructions.
  • Sedation, anticoagulation, and a pain flare can alter the return plan.

Common temporary symptoms or burdens

  • Needle-site soreness or bruising
  • Temporary numbness or tingling
  • Short-lived pain flare

Contact the treating team when

  • Fever, drainage, rapidly increasing redness or swelling, chest pain, shortness of breath, new severe calf symptoms, or a sudden major loss of function.
  • Pain or neurologic symptoms that are severe, rapidly worsening, or materially different from the expected plan.
  • Progressive weakness, spreading numbness, a burn or skin injury, or persistent drainage from a needle site.

Usual reassessment point

A clinical check over several weeks is common; durable response is judged over longer follow-up.

Variables that may change the trajectory

  • Targets and lesion technique
  • Block strategy
  • Native versus replaced-knee context
  • Pain mechanism
  • Rehabilitation and activity

Timeline note: These are discussion ranges, not promises. The treating team may use a different plan based on diagnosis, technique, health, work, and response.

Peripheral nerve stimulation

Before treatment

Complete the cause-focused evaluation, identify a plausible nerve target, review device type, skin/infection risk, medications, work demands, coverage, and follow-up availability.

Treatment or procedure day

A lead is placed near the selected nerve and tested. Temporary systems connect to an external stimulator; implanted systems require a separate implantation pathway.

First 72 hours

Protect the dressing and lead, learn device use, and expect localized soreness. Follow bathing and activity restrictions exactly.

First two weeks

Programming may be adjusted while the lead site is monitored. Daily routines may need modification to prevent lead traction.

Weeks two through six

Use the agreed pain and function goals to judge response while continuing device care and rehabilitation.

Later recovery

Temporary leads are removed at the planned end of treatment; implanted systems require ongoing programming and hardware follow-up.

Expected time to benefit

During the treatment period; timing and carryover depend on system, target, condition, and response.

Return to work and activity

  • Desk work may be possible quickly if the lead and dressing can be protected.
  • Heavy, repetitive, wet, or contact work may conflict with lead restrictions and needs a specific plan.

Common temporary symptoms or burdens

  • Lead-site soreness or itching
  • Skin irritation from adhesive
  • Tingling or uncomfortable stimulation
  • Temporary activity inconvenience from the external device

Contact the treating team when

  • Fever, drainage, rapidly increasing redness or swelling, chest pain, shortness of breath, new severe calf symptoms, or a sudden major loss of function.
  • Pain or neurologic symptoms that are severe, rapidly worsening, or materially different from the expected plan.
  • Drainage, spreading redness, fever, lead displacement, device malfunction, new weakness, or an exposed/damaged lead.

Usual reassessment point

Programs reassess during programming and at the end of a temporary course; longer follow-up determines whether benefit persists.

Variables that may change the trajectory

  • Device type
  • Nerve target
  • Lead stability
  • Programming
  • Pain mechanism
  • Skin, infection, and work context

Timeline note: These are discussion ranges, not promises. The treating team may use a different plan based on diagnosis, technique, health, work, and response.

Cryoneurolysis

Before treatment

Confirm the diagnosis, target nerve, chronic versus perioperative context, product/labeling, skin and neurologic status, medications, and coverage.

Treatment or procedure day

The target is mapped and treated through a small probe after local anesthetic; several treatment cycles may be used.

First 72 hours

Localized soreness, swelling, bruising, and numbness are common discussion points. Protect numb skin and follow wound instructions.

First two weeks

The numb area and pain response become clearer; monitor for dysesthesia, skin injury, or unexpected weakness.

Weeks two through six

Track activity and symptom change while sensation may remain altered.

Later recovery

Pain and sensation may change as the nerve recovers; a recurrence does not by itself mean the procedure should be repeated.

Expected time to benefit

Potentially early, with duration varying from little benefit to a temporary response measured in weeks or months.

Return to work and activity

  • Many routine activities can resume quickly if the treated area can be protected.
  • Jobs with pressure, heat/cold exposure, balance risk, or reliance on normal skin sensation need specific guidance.

Common temporary symptoms or burdens

  • Numbness or tingling
  • Probe-site tenderness or bruising
  • Temporary pain flare or unusual sensitivity

Contact the treating team when

  • Fever, drainage, rapidly increasing redness or swelling, chest pain, shortness of breath, new severe calf symptoms, or a sudden major loss of function.
  • Pain or neurologic symptoms that are severe, rapidly worsening, or materially different from the expected plan.
  • Blistering or progressive skin injury, spreading redness, unexpected weakness, severe dysesthesia, or a fall related to altered sensation.

Usual reassessment point

An early site check may be followed by functional reassessment over several weeks.

Variables that may change the trajectory

  • Nerve target
  • Device and freeze protocol
  • Chronic versus perioperative use
  • Skin and neurologic factors
  • Underlying mechanics

Timeline note: These are discussion ranges, not promises. The treating team may use a different plan based on diagnosis, technique, health, work, and response.

What if it works, partly works, or does not work?

Genicular nerve radiofrequency ablation

When response is assessed

Assess after procedure soreness has settled and enough time has passed for the expected effect, commonly over several weeks.

Meaning of partial response

Partial relief may identify a useful pain component while leaving other mechanical, nerve, hip, spine, or whole-person contributors unaddressed.

Repeatability

Repeat is generally discussed after a meaningful prior response wears off, not simply after no response.

Effect on later options

RFA usually preserves later PNS, rehabilitation, orthopedic, or reconstruction options.

Diagnostic information from failure

A block or ablation response can inform—but does not conclusively diagnose—the contribution of the targeted nerves.

Next branch

Revisit the workup, target choice, rehabilitation, medication/whole-person plan, and whether PNS or orthopedic reassessment is more appropriate.

Renew diagnostic or orthopedic evaluation when

  • A replaced knee has not had a sufficiently complete cause-focused evaluation.
  • New instability, swelling, wound change, systemic illness, injury, deformity, or major loss of function develops.

Peripheral nerve stimulation

When response is assessed

Judge response during the programmed treatment window and again after temporary-lead removal when carryover is part of the proposed benefit.

Meaning of partial response

Partial improvement may justify programming or goal adjustment, but it does not automatically justify permanent implantation.

Repeatability

Reprogramming, another temporary course, implantation, revision, or removal each requires a separate decision.

Effect on later options

Temporary PNS usually preserves later options; implanted hardware can affect imaging and future procedural planning.

Diagnostic information from failure

Stimulation response may support a nerve-mediated component but is not a definitive diagnosis and does not erase other contributors.

Next branch

Recheck target selection, device programming, rehabilitation, medication and whole-person factors, and whether orthopedic or other-specialty reassessment is needed.

Renew diagnostic or orthopedic evaluation when

  • The cause-focused workup was incomplete or symptoms changed since it was completed.
  • New wound, systemic, neurologic, vascular, instability, swelling, injury, or major functional symptoms appear.

Cryoneurolysis

When response is assessed

Assess after local soreness settles and over the protocol's expected response window.

Meaning of partial response

A partial response may indicate that the target contributes to pain while other knee, nerve, or whole-person factors remain.

Repeatability

Repeat is possible in some settings but requires review of the first response, sensation, skin effects, and continuing diagnosis.

Effect on later options

Failure generally leaves later RFA, PNS, rehabilitation, and orthopedic options available.

Diagnostic information from failure

Response may be informative about the treated nerve but does not prove or exclude a specific knee diagnosis.

Next branch

Reconsider the nerve target, pain source, rehabilitation, and whether a different pain-focused or orthopedic conversation is appropriate.

Renew diagnostic or orthopedic evaluation when

  • Unexpected weakness, progressive sensory change, skin injury, or new vascular symptoms occur.
  • The knee develops swelling, instability, systemic illness, injury, deformity, or major functional decline.

Questions to ask and next links

Genicular nerve radiofrequency ablation

  • What has been ruled out before treating pain signaling?
  • Do you use a diagnostic block and what result matters?
  • Which nerves and RFA technique will be used?
  • How and when will we judge benefit?
  • What happens if relief is partial or temporary?
Open treatment guideFind programs

Peripheral nerve stimulation

  • Why is this nerve the proposed target?
  • Is the system temporary or implanted?
  • What workup makes a pain target reasonable?
  • How will I manage the lead and device?
  • What happens if stimulation helps only partly or stops helping?
Open treatment guideFind programs

Cryoneurolysis

  • Is this for chronic OA pain or perioperative pain?
  • Which nerve is being treated and why?
  • What evidence applies to this exact technique?
  • What numbness or activity changes should I expect?
  • What is the plan if pain does not improve?
Open treatment guideFind programs

Sources and review date

Clinical comparison content reviewed 2026-08-14. Source access reviewed 2026-08-14.